About: http://data.cimple.eu/news-article/53749cc47a74b7f02b2121d84a9df307dfe513f99c6a6d400adabe1b

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/53749cc47a74b7f02b2121d84a9df307dfe513f99c6a6d400adabe1b Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Novartis announced Thursday it will join forces with fellow Swiss pharmaceutical giant Roche to produce tocilizumab, a drug being tested for its effectiveness against Covid-19-linked pneumonia. It is the third time Novartis has made its production capacities available to a competitor during the coronavirus pandemic, as several laboratories strike unprecedented partnerships to fight the global crisis. Novartis is already collaborating with BioNTech and CureVac in producing Covid-19 vaccines. The new tocilizumab deal will see Roche's manufacturing expertise transferred to the Novartis Drug Substance Singapore production site during the second quarter of 2021. "Novartis is fully committed to collaborating with Roche in offering our proven biologics production capabilities," said Steffen Lang, the firm's technical operations chief. "As one of the world's largest producers of medicines, Novartis can mobilise its manufacturing capabilities on multiple fronts." Sold as Actemra or RoActemra depending on the market, tocilizumab is a treatment for rheumatoid arthritis which is also being tested in clinical trials investigating its safety and efficacy against Covid-19-associated pneumonia. The injected treatment has suffered several setbacks in clinical trials. However, a large British study published in February reported encouraging results, particularly in reducing the risk of death. In January, Novartis announced an agreement with Pfizer-BioNTech to provide manufacturing capacity for its Covid-19 jabs. In March, it then struck an agreement to manufacture the mRNA and bulk drug product for CureVac's Covid-19 candidate vaccine. Faced with the desperate shortage of vaccine production capacity in dealing with the pandemic, unprecedented cooperation has been struck between laboratories. Novartis did not join the race to produce a Covid-19 jab, being no longer involved in vaccines following a major reorganisation in 2015. Its vaccines were sold to the British firm GlaxoSmithKline, with the exception of its influenza jabs which were sold off separately to the Australian laboratory CSL. noo/rjm/nl/wai
schema:headline	Novartis, Roche team up on Covid pneumonia drug
schema:mentions	Novartis Hoffmann-La Roche Medication GlaxoSmithKline Influenza vaccine Pneumonia Jab Switzerland Singapore Messenger RNA Pandemic Coronavirus disease United Kingdom Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Tocilizumab Rheumatoid arthritis CureVac Becky Mode Biopharmaceutical »more»
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-04-15 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	85 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software